Baloxavir Marboxil Drug Asset Due Diligence Report 2026

This Baloxavir Marboxil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Baloxavir Marboxil can convert its Small molecule drug profile and CEN biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Baloxavir Marboxil (query alias: baloxavir)
Modality / target	Small molecule drug; CEN; CEN inhibitors
Highest global status	Approved
Originator	Shionogi & Co., Ltd.
Active developers	Roche Pharma (Schweiz) AG, Roche Registration GmbH, China Pharmaceutical University

The MCP disease footprint includes Influenza, Human, Influenza A virus infection, Influenza B virus infection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600126666	Phase 4	Not yet recruiting	800	time to alleviation of symptoms
CTR20261650	Not Applicable	进行中（尚未招募）	42	Not disclosed
CTR20261638	Not Applicable	进行中（尚未招募）	38	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza

Phase 2; n=6; evaluation: Negative. Reported fields: AE = Baloxavir administration was well tolerated, and no adverse events could be attributed to the administered antiviral treatment

A Phase III, Randomized, Open-Label, Active-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Patients 1 to <12 Years of Age With Influenza Symptoms

Phase 3; n=100; evaluation: not stated. Reported fields: -; -; -

A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts

Phase 3; n=4138; evaluation: not stated. Reported fields: Percentage of HHCs With Virological Influenza Transmission by Day 5: Adjusted OR (BMX vs Placebo) = 0.68(95.38% CI, 0.50 - 0.93), P-Value = 0.013; Percentage of HHCs With Virological Influenza Transmission by Day 5: Adjusted OR (BMX vs Placebo) = 0.68(95.38% CI, 0.50 - 0.93), P-Value = 0.013; Percentage of HHCs With Virological Influenza Transmission by Day 5: Adjusted OR (BMX vs Placebo) = 0.68(95.38% CI, 0.50 - 0.93), P-Value = 0.013

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Baloxavir Marboxil addresses Influenza, Human, Influenza A virus infection, Influenza B virus infection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-05-19	Roche signs generic Xofluza licensing deal with Medicines Patent Pool for 129 countries	Approved	Financial terms not disclosed
2023-03-22	重磅新闻 \| 罗氏制药中国与华润医药商业就抗流感创新药物速福达®达成战略合作	Approved	Financial terms not disclosed
2016-02-29	Shionogi Enters into a License and Collaboration Agreement with Roche for its Anti-Flu Drug, S-033188	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Process for manufacturing baloxavir marboxil”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO